- Home
- ZENV vs XLO Comparison
ZENV vs XLO Comparison
Compare ZENV & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZENV | XLO |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 41.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZENV | XLO |
|---|---|---|
| Price | $0.89 | $0.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 33.7K | ★ 333.3K |
| Earning Date | 03-16-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,426,369.00 | $31,804,000.00 |
| Revenue This Year | $12.75 | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.80 | ★ 588.40 |
| 52 Week Low | $0.86 | $0.59 |
| 52 Week High | $2.74 | $1.70 |
Technical Indicators
Market Signals| Indicator | ZENV | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 40.75 |
| Support Level | $0.86 | $0.63 |
| Resistance Level | $1.00 | $0.63 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 26.95 | 32.53 |
Price Performance
Historical ComparisonAbout ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.